E
Elizabeth Broadhurst
Researcher at University of Cambridge
Publications - 5
Citations - 420
Elizabeth Broadhurst is an academic researcher from University of Cambridge. The author has contributed to research in topics: Vasculitis & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 174 citations.
Papers
More filters
Journal ArticleDOI
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
Michael Walsh,Peter A. Merkel,Chen-Au Peh,Wladimir Szpirt,Xavier Puéchal,Shouichi Fujimoto,Carmel M. Hawley,Nader Khalidi,Oliver Floßmann,Ron Wald,Louis Girard,Adeera Levin,Gina Gregorini,Lorraine Harper,William F. Clark,Christian Pagnoux,Ulrich Specks,Lucy Smyth,Vladimir Tesar,Toshiko Ito-Ihara,Toshiko Ito-Ihara,Janak de Zoysa,Wojciech Szczeklik,Luis Felipe Flores-Suárez,Simon Carette,L. Guillevin,Charles D. Pusey,Alina Casian,Biljana Brezina,Andrea Mazzetti,Carol A. McAlear,Elizabeth Broadhurst,Donna Reidlinger,Samir Mehta,Natalie Ives,David Jayne,Pexivas Investigators Pexivas Investigators +36 more
TL;DR: Among patients with severe ANCA-associated vasculitis, the use of plasma exchange did not reduce the incidence of death or ESKD, and a reduced-dose regimen of glucocorticoids was noninferior to a standard- dose regimen with respect to death orESKD.
Journal ArticleDOI
Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)
Seerapani Gopaluni,Rona M Smith,Donna Goymer,Hugh Cahill,Elizabeth Broadhurst,Elizabeth F. Wallin,Mark McClure,Afzal N. Chaudhry,David Jayne +8 more
TL;DR: The ALEVIATE trial as mentioned in this paper evaluated the efficacy and safety of alemtuzumab, at two different doses, in inducing remission in refractory vasculitis patients, and the safety profile was acceptable.
Journal ArticleDOI
302. alemtuzumab for relapsing and refractory primary systemic vasculitis – a trial of efficacy and safety (aleviate): a randomised open-label phase ii clinical trial
Seerapani Gopaluni,Donna Goymer,Mark McClure,Hugh Cahill,Elizabeth Broadhurst,Rona M Smith,David Jayne +6 more
Journal ArticleDOI
Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
David Jayne,Michael Walsh,Petra Merkel,Chen Au Peh,Wladimir Szpirt,Xavier Puéchal,Shouichi Fujimoto,Carmel M. Hawley,Nader Khalidi,Rachel B Jones,Oliver Flossmann,Ron Wald,Louis Girard,Adeera Levin,Gina Gregorini,Lorraine Harper,William C. Clark,Christian Pagnoux,Ulrich Specks,Lucy J.C. Smyth,Toshiko Ito-Ihara,Janak de Zoysa,Biljana Brezina,Andrea Mazzetti,Carol A. McAlear,Donna Reidlinger,Samir Mehta,Natalie Ives,Elizabeth Brettell,Hugh Jarrett,Keith Wheatley,Elizabeth Broadhurst,Alina Casian,Charles D. Pusey +33 more
TL;DR: The clinical efficacy of plasma exchange in addition to immunosuppressive therapy and glucocorticoids with respect to death and end-stage renal disease in patients with severe anti-neutrophil cytoplasm antibody-associated vasculitis was determined, meeting the non-inferiority hypothesis.
Journal ArticleDOI
Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT
Toshiko Ito-Ihara,Christian Pagnoux,Donna Reidlinger,Janak de Zoysa,Lorraine Harper,Gina Gregorini,Shouichi Fujimoto,Andrea Mazzetti,Elizabeth Broadhurst,Hugh Jarrett,Chen Au Peh,Ludmila BRANIŞTE,German Freiberg,Germana Volpe,Benavides-Riveros, Carlos L.,Bárbara Cristina Araujo Uehara,gagabah,Холиков Музаффар Абдигаппарович,AMNH Mammalogy,Yusing Gu,Kyssia Lilian Pessoa Trindade,Michael Benton,Thomas Hoefer,MARIA YASMIN DE CARVALHO NORONHA,Philip T. Gressman,A. U. Isakhanyan,Yifei Yan,Ye Wu,Izkk- MkW- vkfnR; fd'kksj lkjos,None Cathy Whitlock,Stanley Masunda,Hannah K. Jarman,w9mpzru108,Claire Wrobel +33 more
TL;DR: In this article , the clinical efficacy of plasma exchange in addition to immunosuppressive therapy and glucocorticoids with respect to death and end-stage renal disease in patients with severe anti-neutrophil cytoplasm antibody-associated vasculitis was evaluated.